Bio E vax candidate gets SEC nod for phase III trials

Bio E vax candidate gets SEC nod for phase III trials The phase III trials of the recombinant protein vaccine will be conducted on 1,268 healthy volunteers in the 18 to 80 age bracket across 15 sites in India to evaluate the immunogenicity and safety of the vaccine. This is part of a larger global phase III study, Biological E said on Saturday. https://ift.tt/eA8V8J